Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Share-based Compensation (2022 - 2025)

Entrada Therapeutics has reported Share-based Compensation over the past 4 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $4.4 million for Q4 2025, down 7.28% from a year ago — trailing twelve months through Dec 2025 was $19.6 million (up 9.46% YoY), and the annual figure for FY2025 was $19.6 million, up 9.46%.
  • Share-based Compensation for Q4 2025 was $4.4 million at Entrada Therapeutics, down from $5.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TRDA hit a ceiling of $5.1 million in Q3 2025 and a floor of $1.8 million in Q1 2022.
  • Median Share-based Compensation over the past 4 years was $3.8 million (2023), compared with a mean of $3.8 million.
  • Biggest five-year swings in Share-based Compensation: surged 53.57% in 2023 and later fell 7.28% in 2025.
  • Entrada Therapeutics' Share-based Compensation stood at $2.9 million in 2022, then skyrocketed by 33.28% to $3.8 million in 2023, then increased by 22.36% to $4.7 million in 2024, then decreased by 7.28% to $4.4 million in 2025.
  • The last three reported values for Share-based Compensation were $4.4 million (Q4 2025), $5.1 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.